secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIMEDX GROUP, INC. (MDXG)
CIK:        0001376339
Form:       8-K
Filed at:   2022-12-08T23:59:59+00:00
Accession:  0001193125-22-300537
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

MiMedx licenses Turn's PermaFusion platform for $1M upfront, up to $9.55M in milestones for FleX AM product rights
--------------------------------------------------------------------------------

- MiMedx obtains exclusive worldwide license to Turn's PermaFusion antimicrobial platform for wound, burn, and surgical fields.
- Upfront cash payment of $1 million; potential milestone payments up to $9.55 million upon FDA 510(k) clearance of FleX AM product.
- MiMedx acquires commercial rights to FleX AM, a particulate bovine collagen powder with antimicrobial properties, expected FDA clearance in 2023.
- Turn will receive royalties on sales of products developed using the licensed technology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1376339/000119312522300537/0001193125-22-300537-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1376339/000119312522300537/d396655d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-300537

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer